Skip to main
PGNY

Progyny (PGNY) Stock Forecast & Price Target

Progyny (PGNY) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Progyny Inc. is experiencing significant growth in its fertility services, evidenced by a 39% year-over-year increase in egg retrievals and bankings, reflecting heightened demand particularly among women in the tech sector. The company anticipates substantial revenue opportunities through the launch of its fully-insured product offering, which is expected to align with increasing state mandates for IVF, thus expanding its market potential. Furthermore, Progyny has achieved near 100% client retention, with a notable 30% of clients opting to enhance their benefits, while the number of covered lives with access to additional services is projected to grow from 1.5 million in 2025 to 2.7 million in 2026, underlining a strong expansion trajectory.

Bears say

Progyny Inc faces fundamental challenges that contribute to a negative outlook on its stock due to economic uncertainty and competitive pressures in the fertility benefits market. The company has experienced a reduction in expected covered lives, decreasing from approximately 7.6 million to 7.2 million, coupled with a decline in guidance of adjusted EBITDA estimates to a range of $224 to $239 million, below previous expectations. Additionally, the potential impact of consumers hesitating to utilize expensive fertility benefits amid rising unemployment and a competitive market landscape raises concerns about Progyny's future revenue growth and overall financial stability.

Progyny (PGNY) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Progyny and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Progyny (PGNY) Forecast

Analysts have given Progyny (PGNY) a Buy based on their latest research and market trends.

According to 9 analysts, Progyny (PGNY) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Progyny (PGNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.